Additionally, the FDA has approved therapy with atezolizumab for TNBC containing 1% PD-L1 positive immune cells in the tumor biopsy, based on the IMpassion130 clinical trial (NCT02425891) [8]. The gene discussed is CD274; the disease is neoplasm.